European Medicines Agency (EMA) grants Orphan Designation for AOC 1001
The FDA cleared Avidity to proceed with the phase-I/II Marinatm trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1)…
Recover your password.
A password will be e-mailed to you.
Recover your password.
A password will be e-mailed to you.